New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc. (‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart Failure. Heart failure (HF) is a leading cause of hospitalization in the United States. Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss a